We have located links that may give you full text access.
Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma.
Pancreas 2022 September 14
OBJECTIVES: Pharmacological ascorbate (P-AscH-, high-dose, intravenous vitamin C) has shown promise as an adjuvant therapy for pancreatic ductal adenocarcinoma (PDAC) treatment. The objective of this study was to determine the effects of P-AscH- when combined with PDAC chemotherapies.
METHODS: Clonogenic survival, combination indices, and DNA damage were determined in human PDAC cell lines treated with P-AscH- in combination with 5-fluorouracil, paclitaxel, or FOLFIRINOX (combination of leucovorin, 5-fluorouracil, irinotecan, oxaliplatin). Tumor volume changes, overall survival, blood analysis, and plasma ascorbate concentration were determined in vivo in mice treated with P-AscH- with or without FOLFIRINOX.
RESULTS: P-AscH- combined with 5-fluorouracil, paclitaxel, or FOLFIRINOX significantly reduced clonogenic survival in vitro. The DNA damage, measured by γH2AX protein expression, was increased after treatment with P-AscH-, FOLFIRINOX, and their combination. In vivo, tumor growth rate was significantly reduced by P-AscH-, FOLFIRINOX, and their combination. Overall survival was significantly increased by the combination of P-AscH- and FOLFIRINOX. Treatment with P-AscH- increased red blood cell and hemoglobin values but had no effect on white blood cell counts. Plasma ascorbate concentrations were significantly elevated in mice treated with P-AscH- with or without FOLFIRINOX.
CONCLUSIONS: The addition of P-AscH- to standard of care chemotherapy has the potential to be an effective adjuvant for PDAC treatment.
METHODS: Clonogenic survival, combination indices, and DNA damage were determined in human PDAC cell lines treated with P-AscH- in combination with 5-fluorouracil, paclitaxel, or FOLFIRINOX (combination of leucovorin, 5-fluorouracil, irinotecan, oxaliplatin). Tumor volume changes, overall survival, blood analysis, and plasma ascorbate concentration were determined in vivo in mice treated with P-AscH- with or without FOLFIRINOX.
RESULTS: P-AscH- combined with 5-fluorouracil, paclitaxel, or FOLFIRINOX significantly reduced clonogenic survival in vitro. The DNA damage, measured by γH2AX protein expression, was increased after treatment with P-AscH-, FOLFIRINOX, and their combination. In vivo, tumor growth rate was significantly reduced by P-AscH-, FOLFIRINOX, and their combination. Overall survival was significantly increased by the combination of P-AscH- and FOLFIRINOX. Treatment with P-AscH- increased red blood cell and hemoglobin values but had no effect on white blood cell counts. Plasma ascorbate concentrations were significantly elevated in mice treated with P-AscH- with or without FOLFIRINOX.
CONCLUSIONS: The addition of P-AscH- to standard of care chemotherapy has the potential to be an effective adjuvant for PDAC treatment.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app